RIL Q4 preview: O2C likely to drive 17% rise in EBITDA; Jio ARPU may improve to ₹179
Nomura Group expects pharma firms to report decent earnings; picks Zydus Lifesciences, Alkem Lab, Medplus
Infosys Earnings Preview: Q4 likely to be a weak quarter, say experts; here are key things to watch out for